MG
BIO.B icon

Michael Gelband’s Bio-Rad Laboratories Class B BIO.B Stock Holding History

Michael Gelband’s Portfolio BIO.B Stock Details BIO.B Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed – – 1859
2023
Q1 		$0 Buy
+1
New +$464 ﹤0.01% 1763

Other funds holding BIO.B

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
WT
Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Michael Gelband's BIO.B Position: Q2 2023 in Review

Michael Gelband sold out of Bio-Rad Laboratories Class B (BIO.B) in Q2 2023, closing a stake of 1 share.

Michael Gelband first reported a position in BIO.B in Q1 2023 and held it in 1 quarter. The position peaked at $0 in Q1 2023. 7 funds tracked by Wall St. Rank hold BIO.B as of Q2 2023.

  • Michael Gelband reported no remaining Bio-Rad Laboratories Class B position as of Q2 2023 after selling out during the quarter.
  • Michael Gelband sold 1 Bio-Rad Laboratories Class B share in Q2 2023.
  • Michael Gelband first reported a position in Bio-Rad Laboratories Class B in Q1 2023 and held it in 1 quarter.
  • Michael Gelband's Bio-Rad Laboratories Class B position peaked at $0 in Q1 2023.
  • 7 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class B as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.